Estimation of Ischemia Modified Albumin (IMA) levels in patients with acute coronary syndrome

被引：59

作者：

Gurumurthy P. ^{[1
]}

Borra S.K. ^{[1
]}

Yeruva R.K.R. ^{[1
]}

Victor D. ^{[1
]}

Babu S. ^{[1
]}

Cherian K.M. ^{[2
]}

机构：

[1] Department of Biochemistry, Frontier Lifeline Hospital, Dr. K. M. Cherian's Heart Foundation, Mogappair, Chennai 600101, Tamilnadu, RC-30, Ambattur Estate Road

[2] Department of Cardiology, Frontier Lifeline Hospital, Dr. K. M. Cherian's Heart Foundation, Mogappair, Chennai 600101, Tamilnadu, RC-30, Ambattur Estate Road

来源：

Indian Journal of Clinical Biochemistry | 2014年 / 29卷 / 3期

关键词：

Acute coronary syndrome; Biomarker; Ischemia; Ischemia modified albumin; Reactive oxygen species;

D O I：

10.1007/s12291-013-0367-3

中图分类号：

学科分类号：

摘要：

Myocardial ischemia produces free radicals that catalyze a series of oxidative reactions that damage healthy tissues. The N-terminal sequence of albumin is one of the proteins modified by these highly reactive oxygen species and forms the ischemia modified albumin (IMA). This study involves investigations undertaken in different study groups to assess the levels of IMA. Mean serum IMA levels (U/mL) in patients with ST-segment elevated myocardial infarction (92.1 ± 10.6), non-ST-segment elevated myocardial infarction (87.3 ± 5.95) and unstable angina (UA) (88.9 ± 6.16) were significantly higher than non-cardiac chest pain (77.9 ± 6.69) and also healthy subjects (54.7 ± 17.2) (p < 0.001). IMA is a highly sensitive marker and has a high predictive value, which might prove the usefulness of this biomarker for early detection of myocardial ischemia. These data indicate a possible role of the IMA test in the early triage of patients with chest pain. © 2013 Association of Clinical Biochemists of India.

引用

页码：367 / 371

页数：4

共 24 条

[1]

Storrow A.B., Gibler W.B., Chest pain centers: Diagnosis of acute coronary syndromes, Annals of Emergency Medicine, 35, 5, pp. 449-461, (2000)

[2]

Panteghini M., Role and importance of biochemical markers in clinical cardiology, European Heart Journal, 25, 14, pp. 1187-1196, (2004)

[3]

Lin J.C., Apple F.S., Murakami M.M., Luepker R.V., Rates of Positive Cardiac Troponin I and Creatine Kinase MB Mass among Patients Hospitalized for Suspected Acute Coronary Syndromes, Clinical Chemistry, 50, 2, pp. 333-338, (2004)

[4]

Cho D.K., Choi J.O., Kim S.H., Et al., Ischemia-modified albumin is a highly sensitive serum marker of transient myocardial ischemia induced by coronary vasospasm, Coron Artery Dis, 18, pp. 83-87, (2007)

[5]

Lindahl B., Detection of myocardial damage - Are the troponins the ultimate solution?, Scandinavian Cardiovascular Journal, 35, 4, pp. 229-232, (2001)

[6]

Panteghini M., Acute coronary syndrome: Biochemical strategies in the troponin era, Chest, 122, 4, pp. 1428-1435, (2002)

[7]

Collinson P.O., Gaze D.C., Ischemia-modified albumin: Clinical utility and pitfalls in measurement, J Clin Pathol, 61, pp. 1025-1028, (2008)

[8]

Marx G., Chevion M., Site-specific modification of albumin by free radicals, Biochem J, 236, pp. 397-400, (1985)

[9]

Gidenne S., Ceppa F., Fontan E., Perrier F., Burnat P., Analytical performance of the Albumin Cobalt Binding (ACB) test on the Cobas MIRA Plus analyzer, Clinical Chemistry and Laboratory Medicine, 42, 4, pp. 455-461, (2004)

[10]

Bar-Or D., Curtis G., Rao N., Et al., Characterization of the Co<sup>2+</sup> and Ni<sup>2+</sup> binding amino-acid residues of the N terminus of human albumin: An insight into the mechanism of a new assay for myocardial ischemia, Eur J Biochem, 268, pp. 42-47, (2001)

← 1 2 3 →